Literature DB >> 8610271

Locally advanced noninflammatory breast cancer.

K K Hunt1, F C Ames, S E Singletary, A U Buzdar, G N Hortobagyi.   

Abstract

Treatment of locally advanced noninflammatory breast cancer has changed markedly over the past 50 years. Haagensen's description of the clinical signs that define inoperable and operable tumors was the first realization that radical surgery alone could not cure the majority of women with locally advanced disease. Studies of the use of local therapy alone (surgery or radiation therapy) confirmed that most patients developed both distant metastatic disease and a high rate of local-regional failure. Combination surgery and radiation therapy regimens improved local control but did not influence long-term survival. The advent of successful multimodal regimens incorporating systemic treatment (chemotherapy or chemohormonal therapy) as well as local therapy (surgery and radiation) has significantly improved disease-free and overall survival as well as local-regional control. The benefits of neoadjuvant and adjuvant chemotherapy regimens have been debated. Neoadjuvant therapy allows clinical and pathologic assessment of tumor response to the chemotherapy regimen. In addition, local-regional control seems to be improved, and reductions in the size of the primary tumor allow breast-preserving procedures, even in patients initially not believed to be candidates for resection. Longer follow-up of these conservatively treated patients will be needed, however, to determine whether local-regional control is preserved.

Entities:  

Mesh:

Year:  1996        PMID: 8610271     DOI: 10.1016/s0039-6109(05)70446-1

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN: 0039-6109            Impact factor:   2.741


  5 in total

1.  Prognostic factors affecting locoregional recurrence in patients with stage IIIB noninflammatory breast cancer.

Authors:  Kaptan Gülben; Uğur Berberoğlu; Aziz Cengiz; Hüseyin Altınyollar
Journal:  World J Surg       Date:  2007-09       Impact factor: 3.352

2.  Neoadjuvant treatment with paclitaxel and epirubicin in invasive breast cancer: a phase II study.

Authors:  David Sarid; Ilan G Ron; Fani Sperber; Yona Stadler; Perry Kahan; Felix Kovner; Rami Ben-Yosef; Sylvia Marmor; Yulia Grinberg; Natalie Maimon; Juliana Weinstein; Neora Yaal-Hahoshen
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

Review 3.  Role of Hyperthermia in Breast Cancer Locoregional Recurrence: A Review.

Authors:  Sergio Maluta; Merel Willemijn Kolff
Journal:  Breast Care (Basel)       Date:  2015-10-16       Impact factor: 2.860

Review 4.  Locally advanced breast cancer in developing countries: the place of surgery.

Authors:  Justus P Apffelstaedt
Journal:  World J Surg       Date:  2003-06-06       Impact factor: 3.352

5.  Using MRI to plan breast-conserving surgery following neoadjuvant chemotherapy for early breast cancer.

Authors:  M Bhattacharyya; D Ryan; R Carpenter; S Vinnicombe; C J Gallagher
Journal:  Br J Cancer       Date:  2008-01-22       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.